Literature DB >> 29464969

Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies.

Fernando Gil1, Iván L Calderón2, Juan A Fuentes2, Daniel Paredes-Sabja1.   

Abstract

Clostridioides difficile (C. difficile) has become a pathogen of worldwide importance considering that epidemic strains are disseminated in hospitals of several countries, where community-acquired infections act as a constant source of new C. difficile strains into hospitals. Despite the advances in the treatment of infections, more effective therapies against C. difficile are needed but, at the same time, these therapies should be less harmful to the resident gastrointestinal microbiota. The purpose of this review is to present a description of issues associated to C. difficile infection, a summary of current therapies and those in developmental stage, and a discussion of potential combinations that may lead to an increased efficacy of C. difficile infection treatment.

Entities:  

Keywords:  Clostridioides difficile infection; Clostridioides difficile treatment; Clostridium

Mesh:

Substances:

Year:  2018        PMID: 29464969     DOI: 10.2217/fmb-2017-0203

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  4 in total

1.  Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity.

Authors:  Jesse A Jones; Allan M Prior; Ravi K R Marreddy; Rebecca D Wahrmund; Julian G Hurdle; Dianqing Sun; Kirk E Hevener
Journal:  ACS Chem Biol       Date:  2019-06-26       Impact factor: 5.100

2.  Clostridioides difficile specific DNA adenine methyltransferase CamA squeezes and flips adenine out of DNA helix.

Authors:  Jujun Zhou; John R Horton; Robert M Blumenthal; Xing Zhang; Xiaodong Cheng
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

3.  Antibiotic Resistances and Molecular Characteristics of Clostridioides difficile in ICUs in a Teaching Hospital From Central South China.

Authors:  Xiujuan Meng; Xun Huang; Zhong Peng; Yaowang Wang; Sidi Liu; Cui Zeng; Juping Duan; Ximao Wen; Chenchao Fu; Anhua Wu; Chunhui Li
Journal:  Front Med (Lausanne)       Date:  2021-12-06

4.  Repurposing epigenetic inhibitors to target the Clostridioides difficile-specific DNA adenine methyltransferase and sporulation regulator CamA.

Authors:  Jujun Zhou; John R Horton; Dan Yu; Ren Ren; Robert M Blumenthal; Xing Zhang; Xiaodong Cheng
Journal:  Epigenetics       Date:  2021-09-15       Impact factor: 4.861

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.